Page 15 - 2022-36-中国全科医学

·4490· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

subjects［J］. J Clin Endocrinol Metab，1990，70（5）：1426- adenomas［J］. Front Endocrinol （Lausanne），2020，11：
1430. DOI：10.1210/jcem-70-5-1426. 579606. DOI：10.3389/fendo.2020.579606.
［27］PREDA V A，SEN J，KARAVITAKI N，et al. Etomidate in ［41］COLAO A，GALDERISI M，DI SARNO A，et al. Increased
the management of hypercortisolaemia in Cushing's syndrome： prevalence of tricuspid regurgitation in patients with prolactinomas
a review［J］. Eur J Endocrinol，2012，167（2）：137-143. chronically treated with cabergoline［J］. J Clin Endocrinol
DOI：10.1530/EJE-12-0274. Metab，2008，93（10）：3777-3784. DOI：10.1210/jc.2007-
［28］LAMBERTS S W J，HOFLAND L J. Anniversary review： 1403.
octreotide，40 years later［J］. Eur J Endocrinol，2019，181（5）： ［42］DRAKE W M，STILES C E，BEVAN J S，et al. A follow-
R173-183. DOI：10.1530/EJE-19-0074. up study of the prevalence of valvular heart abnormalities in
［29］COLAO A，PETERSENN S，NEWELL-PRICE J，et al. A hyperprolactinemic patients treated with cabergoline［J］. J Clin
12-month phase 3 study of pasireotide in Cushing's disease［J］. Endocrinol Metab，2016，101（11）：4189-4194. DOI：
N Engl J Med，2012，366（10）：914-924. DOI： 10.1210/jc.2016-2224.
10.1056/NEJMoa1105743. ［43］STILES C E，TETTEH-WAYOE E T，BESTWICK J，et al.
［30］LACROIX A，GU F，GALLARDO W，et al. Efficacy and safety of A meta-analysis of the prevalence of cardiac valvulopathy in
hyperprolactinemic patients treated with Cabergoline［J］. J Clin
once-monthly pasireotide in Cushing's disease：a 12 month clinical
Endocrinol Metab，2019，104（2）:523-538. DOI：10.1210/
trial［J］. Lancet Diabetes Endocrinol，2018，6（1）：17-26.
jc.2018-01071.
DOI：10.1016/S2213-8587(17)30326-1.
［44］FLESERIU M，BILLER B M，FINDLING J W，et al.
［31］MA Z Y，SONG Z J，CHEN J H，et al. Recurrent gain-of-function
Mifepristone，a glucocorticoid receptor antagonist，produces
USP8 mutations in Cushing's disease［J］. Cell Res，2015，25（3）：
clinical and metabolic benefits in patients with Cushing's
306-317. DOI：10.1038/cr.2015.20.
syndrome［J］. J Clin Endocrinol Metab，2012，97（6）：2039-
［32］REINCKE M，SBIERA S，HAYAKAWA A，et al. Mutations in
2049. DOI：10.1210/jc.2011-3350.
the deubiquitinase gene USP8 cause Cushing's disease［J］. Nat
［45］FLESERIU M，MOLITCH M E，GROSS C，et al. A new
Genet，2015，47（1）：31-38. DOI：10.1038/ng.3166.
therapeutic approach in the medical treatment of Cushing's
［33］CASTELLNOU S，VASILJEVIC A，LAPRAS V，et al. SST5
syndrome：glucocorticoid receptor blockade with mifepristone［J］.
expression and USP8 mutation in functioning and silent corticotroph
Endocr P ract，2013，19（2）：313-326. DOI：
pituitary tumors［J］. Endocr Connect，2020，9（3）：243-253.
10.4158/EP12149.RA.
DOI：10.1530/EC-20-0035.
［46］GUARDA F J，FINDLING J，YUEN K C J，et al. Mifepristone
［34］DANIEL E，DEBONO M，CAUNT S，et al. A prospective
increases thyroid hormone requirements in patients with central
longitudinal study of Pasireotide in Nelson's syndrome［J］.
hypothyroidism：a multicenter study［J］. J Endocr Soc，2019，3
Pituitary，2018，21（3）：247-255. DOI：10.1007/s11102-
（9）：1707-1714. DOI：10.1210/js.2019-00188.
017-0853-3.
［47］KAMENICKÝ P，DROUMAGUET C，SALENAVE S，et al.
［35］COLAO A，DE BLOCK C，GAZTAMBIDE M S，et al. Managing
Mitotane，metyrapone，and ketoconazole combination therapy as
hyperglycemia in patients with Cushing's disease treated with
an alternative to rescue adrenalectomy for severe ACTH-dependent
pasireotide：medical expert recommendations［J］. Pituitary，
Cushing's syndrome［J］. J Clin Endocrinol Metab，2011，96（9）：
2014，17（2）：180-186. DOI：10.1007/s11102-013-0483-3.
2796-2804. DOI：10.1210/jc.2011-0536.
［36］FERRIERE A，CORTET C，CHANSON P，et al. Cabergoline for
［48］BARBOT M，ALBIGER N，CECCATO F，et al. Combination
Cushing's disease：a large retrospective multicenter study［J］. Eur
therapy for Cushing's disease：effectiveness of two schedules of
J Endocrinol，2017，176（3）：305-314. DOI：10.1530/EJE- treatment：should we start with cabergoline or ketoconazole? ［J］.
16-0662. Pituitary，2014，17（2）：109-117. DOI：10.1007/s11102-
［37］PIVONELLO R，DE MARTINO M C，CAPPABIANCA P， 013-0475-3.
et al. The medical treatment of Cushing's disease：effectiveness of ［49］FEELDERS R A，DE BRUIN C，PEREIRA A M，et al.
chronic treatment with the dopamine agonist cabergoline in patients Pasireotide alone or with cabergoline and ketoconazole in Cushing's
unsuccessfully treated by surgery［J］. J Clin Endocrinol Metab， disease［J］. N Engl J Med，2010，362（19）：1846-1848.
2009，94（1）：223-230. DOI：10.1210/jc.2008-1533. DOI：10.1056/NEJMc1000094.
［38］WOO I，EHSANIPOOR R M. Cabergoline therapy for Cushing ［50］HINOJOSA-AMAYA J M，VARLAMOV E V，MCCARTNEY
disease throughout pregnancy［J］. Obstet Gynecol，2013，122 S，et al. Hypercortisolemia recurrence in Cushing's disease；
（2 Pt 2）：485-487. DOI：10.1097/AOG.0b013e31829e398a. a diagnostic challenge［J］. Front Endocrinol （Lausanne），
［39］NAKHLEH A，SAIEGH L，REUT M，et al. Cabergoline 2019，10：740. DOI：10.3389/fendo.2019.00740.
treatment for recurrent Cushing's disease during pregnancy［J］. ［51］NEWELL-PRICE J，PIVONELLO R，TABARIN A，et al. Use of
Hormones （Athens），2016，15（3）：453-458. DOI： late-night salivary cortisol to monitor response to medical treatment
10.14310/horm.2002.1685. in Cushing's disease［J］. Eur J Endocrinol，2020，182（2）：
［40］HINOJOSA-AMAYA J M，JOHNSON N，GONZÁLEZ-TORRES 207-217. DOI：10.1530/EJE-19-0695.
C，et al. Depression and impulsivity self-assessment tools to （收稿日期：2022-04-20；修回日期：2022-07-20）
identify dopamine agonist side effects in patients with pituitary （本文编辑：赵跃翠）